Rebound Making Wockhardt An Acquisition Target?
This article was originally published in PharmAsia News
Despite its problems with the U.S. FDA, Wockhardt appears to have rebounded to the extent that it may have made itself a possible acquisition target, including by its fellow Indian drug maker, Lupin.
You may also be interested in...
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.